ELEVATE IPF Phase 2b Results (Deupirfenidone vs. Placebo and Pirfenidone) in patients aged ≥75 years compared with <75 years. CHEST Annual Meeting. 2025. Kulkarni, T et al. [Oral Presentation]
Previous
Previous
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
Next
Next